DERM (Deep Ensemble for Recognition of Malignancy)
Benefits
DERM has the potential to free up dermatology capacity and reduce waiting times by effectively triaging patients with skin lesions where there is a suspicion of cancer. It can discharge around 30% of cases from the urgent suspected skin cancer pathway, allowing more people to be seen more quickly and giving them faster diagnoses.
Details
- Tool name
- DERM (Deep Ensemble for Recognition of Malignancy)
- Organisation
- Skin Analytics
- Status
- pilot
- AI method (as recorded)
- Computer Vision, Machine Learning
- AI method (normalised tags)
- Computer Vision Machine Learning
- Usecase
- Health AI
- Origin
- england.nhs.uk
- Owning team
- NHS England
- Date added
- Scrape date
- 06/04/2026
- Source note
- The National Institute for Health and Care Excellence's (NICE) early value assessment conditionally recommends DERM for use in the NHS over a 3-year period while further evidence is generated to confirm its clinical and cost-effectiveness. DERM is an AI-based skin lesion analysis device with a Class III CE mark. [Source]